Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase

OBJECTIVES: Sotrovimab effectively prevented progression to severe disease and mortality following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether sotrovimab is similarly effective against SARS-CoV-2 Omicron variant infection. METHODS: Observational cohort study of non...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Neil R., Beaty, Laurel E., Bennett, Tellen D., Carlson, Nichole E., Mayer, David A., Molina, Kyle C., Peers, Jennifer L., Russell, Seth, Wynia, Matthew K., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549713/
https://www.ncbi.nlm.nih.gov/pubmed/36229005
http://dx.doi.org/10.1016/j.ijid.2022.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549713/
https://www.ncbi.nlm.nih.gov/pubmed/36229005
http://dx.doi.org/10.1016/j.ijid.2022.10.002

Ejemplares similares